Metabolic Pharmaceuticals Limited (ASX: MBP - News) today announced that CEO
Chris Belyea was interviewed yesterday by Wall Street Reporter. The audiocast
can be accessed at the following Internet link: www.wallstreetreporter.com.
Mr. Belyea discussed the Company's business model, strategy, and progress on
its obesity drug AOD9604, which is currently in Phase 2b clinical trials.
Metabolic is conducting a double-blind, placebo-controlled, 300-patient Phase
2b human clinical trial for its obesity drug AOD9604. The aim of the trial is
to assess the effectiveness of the drug on weight loss in healthy obese patients.
It involves a three-month period of daily oral dosing at 5 different AOD9604
dose levels, and compared to placebo. This is believed to be the largest clinical
trial yet undertaken by an Australian biotech company.
In addition, the Company recently announced pre-clinical success with its newly
licensed analgesic compound ACV1. A pre-clinical safety package is expected
to be completed in the third quarter of 2004, in preparation for a Phase I clinical
trial to start in the fourth quarter.
Metabolic Pharmaceuticals Limited is a biotechnology company based in Melbourne,
Australia, and listed on the Australian Stock Exchange (ASX: MBP - News). The
Company's mission is to develop a pipeline of new pharmaceuticals for world
markets, and currently has active programs aimed at treating obesity (AOD9604
in Phase 2b human trials), pain (ACV1 in preclinical toxicology), type 2 diabetes,
and osteoporosis. Further details are available at www.metabolic.com.au
